Anthony Olson was diagnosed with Myelodysplastic syndromes (MDS) and went on to receive chemo for almost a decade to treat ...

Practical considerations for managing patient adherence on an oral therapy for higher-risk myelodysplastic syndromes.

Luspatercept significantly improved hemoglobin levels in non-transfusion-dependent patients with lower-risk myelodysplastic ...

Did you know Robin Roberts’ openness about her health journey led to an astounding 1,800% increase in bone marrow donor ...

Huntsman Cancer Institute joins other institutions in myeloMATCH, a program that matches patients with clinical trials that ...

Positive topline data from a phase 2 trial show HT-6184, an allosteric NEK7/NLRP3 inflammasome inhibitor, improves ...

Panelists discuss how frontline luspatercept is emerging as an effective treatment for anemia in lower-risk myelodysplastic syndrome (LR-MDS), demonstrating significant improvements in hemoglobin ...

Huntsman Cancer Institute at the University of Utah (the U) has joined other institutions in an innovative clinical trials ...

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Elritercept is a late-stage investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes (MDS) and myelofibrosis (MF).